Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 164 publications
Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial.
Journal: Lancet (London, England)
Published: March 12, 2026
Reversion to normoglycemia with tirzepatide vs semaglutide in participants with obesity and prediabetes: a post hoc analysis of SURMOUNT-5.
Journal: Journal of endocrinological investigation
Published: January 24, 2026
Relationship of early rapid weight loss to efficacy and safety of tirzepatide and semaglutide for obesity: SURMOUNT-5 post hoc analysis.
Journal: The American journal of medicine
Published: December 22, 2025
Monlunabant in adults with obesity and metabolic syndrome: Open-label extension of a phase 2a trial.
Monlunabant in adults with obesity and metabolic syndrome: Open-label extension of a phase 2a trial.
Journal: Diabetes, obesity & metabolism
Published: December 12, 2025
Long-term weight loss outcomes in older adults treated with obesity pharmacotherapy.
Journal: Obesity research & clinical practice
Published: November 01, 2025
A treat-to-target approach for obesity management: A post hoc analysis of the SURMOUNT-5 trial.
Journal: Diabetes, obesity & metabolism
Published: October 31, 2025
Tirzepatide vs. Semaglutide for Obesity Treatment. Reply.
Journal: The New England journal of medicine
Published: October 22, 2025
The important role of comorbidities in the management of obesity.
Journal: Journal of the Endocrine Society
Published: October 01, 2025
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment.
Journal: The New England journal of medicine
Published: September 17, 2025
Approach to the Patient: Clinical Outcomes and Interim Strategies Following Discontinuation of Incretin Agonists.
Journal: The Journal of clinical endocrinology and metabolism
Published: June 17, 2025
Last Updated: 09/26/2026